MICROORGANISMS AND METHODS FOR THE PRODUCTION OF BUTADIENE USING ACETYL-COA
    1.
    发明申请
    MICROORGANISMS AND METHODS FOR THE PRODUCTION OF BUTADIENE USING ACETYL-COA 审中-公开
    使用乙酰辅酶A生产二倍体的微生物和方法

    公开(公告)号:WO2016007365A1

    公开(公告)日:2016-01-14

    申请号:PCT/US2015/038945

    申请日:2015-07-02

    Abstract: The invention provides non-naturally occurring microbial organisms containing butadiene or 2,4- pentadienoate pathways comprising at least one exogenous nucleic acid encoding a butadiene or 2,4-pentadienoate pathway enzyme expressed in a sufficient amount to produce butadiene or 2,4-pentadienoate. The organism can further contain a hydrogen synthesis pathway. The invention additionally provides methods of using such microbial organisms to produce butadiene or 2,4-pentadienoate by culturing a non-naturally occurring microbial organism containing butadiene or 2,4-pentadienoate pathways as described herein under conditions and for a sufficient period of time to produce butadiene or 2,4-pentadienoate. Hydrogen can be produced together with the production of butadiene or 2,4- pentadienoate.

    Abstract translation: 本发明提供了含有丁二烯或2,4-戊二烯酸通路的非天然存在的微生物生物,其包含至少一种编码丁二烯或2,4-戊二烯酸酯途径酶的外源核酸,其表达量足以产生丁二烯或2,4-戊二烯酸 。 生物体还可以含有氢合成途径。 本发明另外提供了使用这种微生物生物体来生产丁二烯或2,4-戊二烯酸盐的方法,其通过在条件和足够的时间段内培养含有本文所述的丁二烯或2,4-戊二烯酸酯途径的非天然存在的微生物生物 生产丁二烯或2,4-戊二烯酸。 可以与丁二烯或2,4-戊二烯酸2,4-二酮的生产一起生产氢。

    MUTANT AOX 1 PROMOTERS
    2.
    发明申请
    MUTANT AOX 1 PROMOTERS 审中-公开
    突变AOX 1启动子

    公开(公告)号:WO2006089329A8

    公开(公告)日:2006-11-02

    申请号:PCT/AT2006000079

    申请日:2006-02-23

    CPC classification number: C12N15/815 C12Y101/03013

    Abstract: A mutant Pichia pastoris alcohol oxidase 1 (AOXl) promoter of the wild type Pichia pastoris AOXl promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of : a) a transcription factor binding site (TFBS) , b) nucleotides 170 to 235 (-784 to -719) , nucleotides 170 to 191 (-784 to -763) , nucleotides 192 to 213 (-762 to -741) , nucleotides 192 to 210 (-762 to -744) , nucleotides 207 to 209 (-747 to -745) , nucleotides 214 to 235 (-740 to -719) , nucleotides 304 to 350 (-650 to -604) , nucleotides 364 to 393 (-590 to -561) , nucleotides 434 to 508 (-520 to -446) , nucleotides 509 to 551 (-445 to -403) , nucleotides 552 to 560 (-402 to -394) , nucleotides 585 to 617 (-369 to -337) , nucleotides 621 to 660 (-333 to -294) , nucleotides 625 to 683 (-329 to -271) , nucleotides 736 to 741 (-218 to -213) , nucleotides 737 to 738 (-217 to -216) , nucleotides 726 to 755 (-228 to -199) , nucleotides 784 to 800 (-170 to -154) or nucleotides 823 to 861 (-131 to -93) of Seq ID No. 1, and combinations thereof .

    Abstract translation: 包含选自以下的至少一种突变的野生型巴斯德毕赤酵母AOX1启动子(SEQ ID No.1)的突变巴斯德毕赤酵母醇氧化酶1(AOX1)启动子:a)转录因子结合位点(TFBS),b )核苷酸170-235(-784至-719),核苷酸170至191(-784至-763),核苷酸192至213(-762至-741),核苷酸192至210(-762至-744),核苷酸 207至209(-747至-745),核苷酸214至235(-740至-719),核苷酸304至350(-650至-604),核苷酸364至393(-590至-561),核苷酸434至 508核苷酸(-520至-446),核苷酸509至551(-445至-403),核苷酸552至560(-402至-394),核苷酸585至617(-369至-337),核苷酸621至660 -333至-294),核苷酸625至683(-329至-271),核苷酸736至741(-218至-213),核苷酸737至738(-217至-216),核苷酸726至755(-228 至-199),核苷酸784至800(-170至-154)或核苷酸823至861(-131至-9 3),Seq ID No.1,及其组合。

    THERAPEUTIC HYPERBRANCHED POLYGLYCEROL ENCAPSULATED BIOMOLECULES
    3.
    发明申请
    THERAPEUTIC HYPERBRANCHED POLYGLYCEROL ENCAPSULATED BIOMOLECULES 审中-公开
    治疗性高分子聚合物包封生物分子

    公开(公告)号:WO2015127347A1

    公开(公告)日:2015-08-27

    申请号:PCT/US2015/017055

    申请日:2015-02-23

    Abstract: Methods for modifying therapeutic agents such as therapeutic biomolecules, such as proteins for improved oral, rectal or transmucosal delivery, as well as compositions made using such methods and methods of administering such compositions to a subject, are disclosed. Specifically, the therapeutic agents are conjugated to hyperbranched polymers (HBPs), such as hyperbranched polyglycerol (HPG). When such conjugates are administered orally to a subject, the HBP protects the therapeutic agent from the acid environment of the stomach and protease attack in the gastro-intestinal tract, while facilitating the absorption of the therapeutic agent in the higher pH environment of the intestines. The methods and compositions are useful for the improved administration of a variety of therapeutic agents to a subject.

    Abstract translation: 公开了用于改善治疗剂如治疗性生物分子的方法,例如用于改善口服,直肠或经粘膜递送的蛋白质,以及使用这些方法制备的组合物以及向受试者施用该组合物的方法。 具体地,治疗剂与超支化聚合物(HBP)缀合,例如超支化聚甘油(HPG)。 当这样的缀合物口服给予受试者时,HBP保护治疗剂免受胃的酸性环境和胃肠道中的蛋白酶侵袭,同时促进治疗剂在肠的较高pH环境中的吸收。 所述方法和组合物可用于改善对受试者施用各种治疗剂。

    PROTEIN EXPRESSION
    4.
    发明申请
    PROTEIN EXPRESSION 审中-公开
    蛋白质表达

    公开(公告)号:WO2013030329A1

    公开(公告)日:2013-03-07

    申请号:PCT/EP2012/066949

    申请日:2012-08-31

    Abstract: The present invention relates to a genetically modified yeast cell comprising: - at least one recombinant promoter operably linked to at least one gene encoding a polypeptide or protein supporting the biosynthesis of polypeptides or proteins within said cell, said at least one gene being located at the native genomic locus of the genetically unmodified wild-type yeast cell, wherein the naturally occurring promoter of the at least one gene encoding the biosynthesis supporting polypeptide or protein is inactivated by at least one mutation within said naturally occurring promoter and, - a secretion cassette comprising a recombinant nucleic acid molecule encoding a protein or polypeptide of interest and a method for producing a recombinant protein or polypeptide of interest using such a cell.

    Abstract translation: 本发明涉及遗传修饰的酵母细胞,其包含: - 至少一个重组启动子,其与编码支持所述细胞内的多肽或蛋白质的生物合成的多肽或蛋白质的至少一个基因可操作地连接,所述至少一个基因位于 遗传上未修饰的野生型酵母细胞的天然基因组座位,其中编码所述生物合成支持多肽或蛋白质的所述至少一个基因的天然存在的启动子通过所述天然存在的启动子内的至少一个突变而失活,和 - 分泌盒包含 编码感兴趣的蛋白质或多肽的重组核酸分子和使用这种细胞产生感兴趣的重组蛋白质或多肽的方法。

    糖脂質の製造方法
    6.
    发明申请
    糖脂質の製造方法 审中-公开
    生产甘油的方法

    公开(公告)号:WO2014061459A1

    公开(公告)日:2014-04-24

    申请号:PCT/JP2013/076958

    申请日:2013-10-03

    Inventor: 高橋 史員

    Abstract:  下記(a)~(c)のいずれかのタンパク質、該タンパク質をコードする遺伝子、該遺伝子を欠失、変異又は発現抑制した形質転換体、並びに該形質転換体を用いた糖脂質の製造方法。 (a)配列番号1で表されるアミノ酸配列からなるタンパク質 (b)配列番号1で表されるアミノ酸配列と50%以上の同一性を有するアミノ酸配列からなり、かつアルコールオキシダーゼ活性を有するタンパク質 (c)配列番号1で表されるアミノ酸配列において、1又は数個のアミノ酸が欠失、置換、挿入、又は付加されたアミノ酸配列からなり、かつアルコールオキシダーゼ活性を有するタンパク質

    Abstract translation: 如下所述的蛋白质(a)至(c)中任一种的蛋白质; 编码蛋白质的基因; 基因被缺失或突变或基因表达被抑制的转化体; 以及使用该转化体生产糖脂的方法:(a)包含SEQ ID NO:1所示的氨基酸序列的蛋白质; (b)包含与SEQ ID NO:1所示的氨基酸序列具有50%以上同一性并具有醇氧化酶活性的氨基酸序列的蛋白质; 和(c)包含由SEQ ID NO:1表示的氨基酸序列中缺失,取代,插入或添加一个或几个氨基酸残基而产生并具有醇氧化酶活性的氨基酸序列的蛋白质。

    MUTANT AOX 1 PROMOTERS
    8.
    发明申请

    公开(公告)号:WO2006089329A2

    公开(公告)日:2006-08-31

    申请号:PCT/AT2006/000079

    申请日:2006-02-23

    CPC classification number: C12N15/815 C12Y101/03013

    Abstract: A mutant Pichia pastoris alcohol oxidase 1 (AOXl) promoter of the wild type Pichia pastoris AOXl promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of : a) a transcription factor binding site (TFBS) , b) nucleotides 170 to 235 (-784 to -719) , nucleotides 170 to 191 (-784 to -763) , nucleotides 192 to 213 (-762 to -741) , nucleotides 192 to 210 (-762 to -744) , nucleotides 207 to 209 (-747 to -745) , nucleotides 214 to 235 (-740 to -719) , nucleotides 304 to 350 (-650 to -604) , nucleotides 364 to 393 (-590 to -561) , nucleotides 434 to 508 (-520 to -446) , nucleotides 509 to 551 (-445 to -403) , nucleotides 552 to 560 (-402 to -394) , nucleotides 585 to 617 (-369 to -337) , nucleotides 621 to 660 (-333 to -294) , nucleotides 625 to 683 (-329 to -271) , nucleotides 736 to 741 (-218 to -213) , nucleotides 737 to 738 (-217 to -216) , nucleotides 726 to 755 (-228 to -199) , nucleotides 784 to 800 (-170 to -154) or nucleotides 823 to 861 (-131 to -93) of Seq ID No. 1, and combinations thereof .

    Abstract translation: 包含选自以下的至少一个突变的野生型巴斯德毕赤酵母AOX1启动子(SEQ ID No.1)的突变型毕赤酵母醇氧化酶1(AOX1)启动子:a)转录因子结合位点(TFBS),b )核苷酸170至235(-784至-719),核苷酸170至191(-784至-763),核苷酸192至213(-762至-741),核苷酸192至210(-762至-744),核苷酸 207至209(-747至-745),核苷酸214至235(-740至-719),核苷酸304至350(-650至-604),核苷酸364至393(-590至-561),核苷酸434至 508(-520至-446),核苷酸509至551(-445至-403),核苷酸552至560(-402至-394),核苷酸585至617(-369至-337),核苷酸621至660( -333至-294),核苷酸625至683(-329至-271),核苷酸736至741(-218至-213),核苷酸737至738(-217至-216),核苷酸726至755(-228 至-199),核苷酸784至800(-170至-154)或核苷酸823至861(-131至-9 3)Seq ID No.1及其组合。

Patent Agency Ranking